Data from Phase 3b ENSURE-AF Study Investigating Once-Daily LIXIANA® (edoxaban)in Patients with Atrial Fibrillation Undergoing Cardioversion Among 13 Daiichi Sankyo Clinical Presentations at ESC Congress 2016 - Seite 4

such as management, quality of life and treatment satisfaction of
patients with AF.[3]

The Prolongation of PREFER in AF Registry was designed to extend
the ongoing PREFER in AF registry to gain further insights on AF
management. The extension to the PREFER in AF registry includes two
additional countries (Belgium and the Netherlands). Data is being
collected from 5,000 patients across 325 centres in the nine European
countries.[4]

About PREFER in VTE

The PREFER in VTE registry enrolled patients in seven European
countries, including Austria, France Germany, Italy, Spain,
Switzerland, and the UK to assess the real-life acute mid-term
management of patients with VTE, the use of healthcare resources, and
to provide data to estimate the costs for 12 months of treatment
following a first-time and/or recurrent VTE diagnosis. In addition,
PREFER in VTE is the first registry of its kind to capture
comprehensive real-world data regarding quality of life, patient
satisfaction and the economic burden of VTE treatment across
Europe.[5]

About Atrial Fibrillation

AF is a condition where the heart beats irregularly and rapidly.
When this happens, blood can pool and thicken in the chambers of the
heart causing an increased risk of blood clots. These blood clots can
break off and travel through the blood stream to the brain (or
sometimes to another part of the body), where they have the potential
to cause a stroke.[6]

AF is the most common type of heart rhythm disorder, and is
associated with substantial morbidity and mortality.[7] More than six
million Europeans are diagnosed with AF, and this figure is expected
to at least double over the next 50 years.[8],[9] Compared to those
without AF, people with the arrhythmia have a 3-5 times higher risk
of stroke.[10] One in five of all strokes are as a result of AF.[9]

About VTE

VTE is an umbrella term for two conditions, deep vein thrombosis
(DVT) and pulmonary embolism (PE). DVT is a disease caused by a blood
clot found in deep veins, usually within the lower leg, thigh or
pelvis, although they can occur in other parts of the body as
well.[11] PE occurs when part of a clot detaches and lodges in the
pulmonary arteries, causing a potentially fatal condition.[12]

VTE is a major cause of morbidity and mortality.[13] A 2007 study
of morbidity and mortality from VTE in six European countries
(France, Germany, Italy, Spain, Sweden and the UK) estimated a total
of approximately 762,000 VTE episodes and a further 370,000
VTE-related deaths each year.[13] There is a high rate of recurrence
after a first VTE event, which is reduced with anticoagulant